XML 22 R13.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation
 3 Months Ended
Apr. 30, 2022
Share-based Payment Arrangement [Abstract]  
Stock-Based Compensation Stock-Based Compensation
The stock-based compensation costs that have been charged against income were as follows (in thousands):

13-Weeks Ended
April 30,
2022		May 1,
2021
Stock-based compensation expense by type:
Stock options
$155 $174 
Restricted stock units2,125 1,788 
Employee stock purchases
158 85 
Director deferred compensation17 6 
  Total stock-based compensation expense2,455 2,053 
Income tax benefit recognized557 479 
  Stock-based compensation expense, net of income tax$1,898 $1,574 

Expense for restricted stock units is shown net of forfeitures which were immaterial for the 13-weeks ended April 30, 2022 and May 1, 2021.
We granted the following equity awards:
13-Weeks Ended
April 30,
2022		May 1,
2021
Stock options
7,212 4,384 
Restricted stock unit awards
107,848 61,241 
Performance-based restricted stock unit awards
49,978 22,492 
Deferred stock units
405 84 

At April 30, 2022, the total compensation cost not yet recognized related to unvested restricted stock unit awards was $12.5 million and the weighted-average period over which such awards are expected to be recognized is 2.4 years. There were no unrecognized compensation costs related to unvested stock options at April 30, 2022.
The weighted-average grant date fair value of stock options granted during the 13-weeks ended April 30, 2022 and May 1, 2021 was $21.46 and $39.73 per share, respectively.
Under the 2012 Non-Employee Director Equity Plan, 6,388 shares of our common stock were awarded during the 13-weeks ended April 30, 2022. No shares of our common stock were awarded during the 13-weeks ended May 1, 2021.
The number of shares purchased, the average price per share, and the weighted-average grant date fair value of shares purchased through our employee stock purchase plan were as follows:
13-Weeks Ended
April 30,
2022		May 1,
2021
Shares purchased14,273 7,445 
Average price per share$61.14 $39.25 
Weighted-average fair value at grant date$18.03 $11.45